{
  "source": "PA-Notification-Procysbi.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1081-14\nProgram Prior Authorization/Notification\nMedication Procysbi® (cysteamine bitartrate)\nP&T Approval Date 7/2013, 7/2014, 7/2015, 6/2016, 6/2017, 6/2018, 6/2019, 6/2020, 6/2021,\n6/2022, 6/2023, 6/2024, 6/2025\nEffective Date 9/1/2025\n1. Background:\nProcysbi (cysteamine bitartrate) is a cystine-depleting agent indicated for the treatment of\nnephropathic cystinosis in adult and pediatric patients 1 years of age and older.\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Procysbi will be approved based on the following criterion:\na. Diagnosis of nephropathic cystinosis\nAuthorization will be issued for 12 months.\nB. Reauthorization\n1. Procysbi will be approved based upon the following criterion:\na. Documentation of positive clinical response to Procysbi therapy\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits may be in place.\n© 2025 UnitedHealthcare Services Inc.\n1\n4. References:\n1. Procysbi [package insert]. Deerfield, IL: Horizon Therapeutics USA, Inc.; February 2022.\n2. Gahl WA, Balog JZ, Kleta R. Nephropathic cystinosis in adults: natural history and effects of\noral cysteamine therapy. Ann Intern Med. 2007 Aug 21;147(4):242-50.\nProgram Prior Authorization/Notification - Procysbi (cysteamine bitartrate)\nChange Control\n7/2013 New program.\n7/2014 Annual review. No changes to the criteria.\n10/2014 Modification to implementation date\n7/2015 Annual review with no ch",
    "tion - Procysbi (cysteamine bitartrate)\nChange Control\n7/2013 New program.\n7/2014 Annual review. No changes to the criteria.\n10/2014 Modification to implementation date\n7/2015 Annual review with no change to criteria.\n6/2016 Annual review with no changes to criteria. Updated background and\nreferences.\n6/2017 Annual review with no changes to criteria. Updated reference.\n6/2018 Annual review with no changes to criteria. Updated reference.\n6/2019 Annual review with no changes to criteria.\n6/2020 Annual review with no changes to criteria. Updated reference.\n6/2021 Annual review with no changes to criteria.\n6/2022 Annual review with no changes to criteria. Updated reference.\n6/2023 Annual review with no changes to criteria. Added state mandate footnote.\n6/2024 Annual review with no changes to criteria.\n6/2025 Annual review with no changes to criteria.\n© 2025 UnitedHealthcare Services Inc.\n2"
  ]
}